Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05357638
Other study ID # NL78096.029.21
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 2, 2022
Est. completion date November 2, 2025

Study information

Verified date April 2023
Source Amsterdam UMC, location VUmc
Contact Erwin EH van Wegen, Dr.
Phone 020-4440461
Email e.vanwegen@amsterdamumc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

People with Parkinson's disease and Multiple Sclerosis experience disabling motor and non-motor symptoms, which respond insufficiently to medication. To adequately alleviate disease burden, physical training is increasing acknowledged as an assisting therapy; however, the optimal dose of exercise in unknown.


Description:

Next to complex motor deficits, people with Parkinson's disease and Multiple Sclerosis experience highly disabling non-motor symptoms; for example, anxiety and depression, cognitive decline, fatigue, and sleep problems. Physical training is increasingly recognized as an assisting and, importantly, safe therapy for these patients to alleviate disease burden. However, the optimal dose (i.e., type, frequency, intensity, duration) of exercise has not yet been established. This study aims to investigate differences in response patterns of motor and non-motor symptoms, blood-based biomarkers of neuroplasticity and neurodegeneration, as well as functional brain connectivity to eight weeks of high intensity interval training [2x/week, ~30 min/session], continuous aerobic training [2x/week, ~50 min/session], or movement advice [+3000 steps/day for 5 days/week monitored with an activity tracker]. Frequently repeated assessment of outcomes measures will be conducted.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date November 2, 2025
Est. primary completion date May 2, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of Parkinson's Disease (PD) or Progressive Multiple Sclerosis (MS) - Hoehn & Yahr stage <4 (PD), Expanded Disability Status Scale score <6 (MS) - Anxiety and/or depressive symptoms; Hospital Anxiety and Depression Scale (HADS) score >=8 points on HADS-A and/or HADS-D - Sufficient cognitive ability to understand training instructions; Montreal Cognitive Assessment score >21 points - Able to participate in intensive physical training, no contra-indications for exercise - Stable medication regime for at least 4 weeks prior to inclusion - Age >=18 years Exclusion Criteria: - Participation in intensive exercise program in the month prior to inclusion - Relapse in the month prior to inclusion (MS) - Symptoms indicating cardiovascular, pulmonary, or metabolic disease or cardiovascular, pulmonary, or metabolic disease which are not under control with medication - abnormal electrocardiography in rest

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
High Intensity Interval Training (HIIT)
8 weeks of HIIT, 2x/week for about 30 minutes/session on a cycle ergometer
Continuous Aerobic Training (CAT)
8 weeks of CAT, 2x/week for about 50 minutes/session on a cycle ergometer
Movement Advice
Weekly step goal, monitored using an activity tracker, +3000 steps/day for 5 days/week, step goal is based on average step count in the 4 weeks of baseline prior to the intervention

Locations

Country Name City State
Netherlands Amsterdam UMC, location VU medical center Amsterdam Noord-Holland

Sponsors (2)

Lead Sponsor Collaborator
Amsterdam UMC, location VUmc Netherlands Brain Foundation

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in anxiety and depressive symptoms The effect of physical training on anxiety and depressive symptoms, measured by the Hospital Anxiety and Depression Scale Baseline (week 0), week 4, week 12, week 16
Secondary Change in disease severity The effect of physical training on disease severity, measured by the Unified Parkinson's Disease Rating Scale (Parkinson's disease) (total score range 0-199, higher score = worse) or Expanded Disability Status Scale (Multiple Sclerosis) Baseline (week 0), week 4, week 12, week 16
Secondary Change in cognitive function (i.e., ability to inhibit cognitive interference) The effect of physical training on cognitive function, measured by the Stroop Color Word Test Baseline (week 0), week 4, week 12, week 16
Secondary Change in cognitive function (i.e., mental flexibility) The effect of physical training on cognitive function, measured by the Trail Making Test Baseline (week 0), week 4, week 12, week 16
Secondary Change in cognitive function (i.e., range of cognitive operations: motor speed, attention, and visuoperceptual functions) The effect of physical training on cognitive function, measured by the Symbol Digit Modalities Test Baseline (week 0), week 4, week 12, week 16
Secondary Change in fatigue The effect of physical training on fatigue, measured by the Checklist Individual Strength fatigue sub-scale Baseline (week 0), week 4, week 12, week 16
Secondary Change in sleep quality The effect of physical training on sleep quality, measured by the Insomnia Severity Index Baseline (week 0), week 4, week 12, week 16
Secondary Change in well-being The effect of physical training on well-being, measured by the Parkinson's Disease Questionnaire (8 items) (Parkinson's disease) or Multiple Sclerosis Impact Scale (29 items) (Multiple Sclerosis) Baseline (week 0), week 4, week 12, week 16
Secondary Change in quality of life The effect of physical training on quality of life, measured by the Short Form health survey (36 items) Baseline (week 0), week 4, week 12, week 16
Secondary Change in motor capacity (i.e., walking speed) The effect of physical training on motor capacity, measured by the 10-Meter Walk Test Baseline (week 0), week 4, week 12, week 16
Secondary Change in motor capacity (i.e., lower extremity function, mobility, and fall risk) The effect of physical training on motor capacity, measured by the Timed Up and Go test Baseline (week 0), week 4, week 12, week 16
Secondary Change in motor capacity (i.e., finger dexterity) The effect of physical training on motor capacity, measured by the Nine Hole Peg Test Baseline (week 0), week 4, week 12, week 16
Secondary Change in activities of daily living The effect of physical training on activities of daily living, measured by the Nottingham Extended Activities of daily living Index Baseline (week 0), week 4, week 12, week 16
Secondary Change in biomarkers of neuroplasticity in blood The effect of physical training on biomarkers of neuroplasticity in blood, measured by Brain Derived Neurotrophic Factor concentration Baseline (week 0), week 4, week 12, week 16
Secondary Change in biomarkers of neurodegeneration in blood The effect of physical training on biomarkers of neurodegeneration in blood, measured by Neurofilament Light concentration Baseline (week 0), week 4, week 12, week 16
Secondary Change in brain morphology The effect of physical training on brain morphology, measured by structural magnetic resonance imaging (MRI) Week 4, week 12
Secondary Change in structural brain connectivity The effect of physical training on structural brain connectivity, measured by diffusion MRI + free-water content Week 4, week 12
Secondary Change in brain connectivity The effect of physical training on brain connectivity, measured by resting state functional MRI Week 4, week 12
Secondary Change in brain iron concentration in the Substantia Nigra The effect of physical training on brain iron concentration in the Substantia Nigra, measured by Quantitative Susceptibility Mapping methodology Week 4, week 12
Secondary Change in brain neuromelanin content The effect of physical training on brain neuromelanin content, measured by neuromelanin-sensitive MRI Week 4, week 12
Secondary Change in daily mood The effect of physical training on daily mood, measured by the Visual Analogue Scale (total sore range 0-10, higher score = better) Weekly assessment from baseline to week 16
Secondary Change in daily anxiety The effect of physical training on daily anxiety, measured by the Visual Analogue Scale (total sore range 0-10, higher score = better) Weekly assessment from baseline to week 16
Secondary Change in daily ability to concentrate The effect of physical training on daily ability to concentrate, measured by the Visual Analogue Scale (total sore range 0-10, higher score = better) Weekly assessment from baseline to week 16
Secondary Change in daily fatigue The effect of physical training on daily fatigue, measured by the Visual Analogue Scale (total sore range 0-10, higher score = better) Weekly assessment from baseline to week 16
Secondary Change in daily sleep quality The effect of physical training on daily sleep quality, measured by the Visual Analogue Scale (total sore range 0-10, higher score = better) Weekly assessment from baseline to week 16
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4

External Links